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OVERVIEW   
  
  
Orthopaedic disorders of the hip are becoming more common in many countries around 
the world, including South Africa.  Conservative medical treatment of severe hip 
disorders might sometimes be ineffective in reducing pain or restoring hip function in 
some patients.  In these patients, surgical intervention, through primary hip 
arthroplasty, remains the only viable option for reducing pain and restoring hip 
function.   
 
The increasing demand for primary hip arthroplasty in South Africa poses a problem 
for many resource-limited orthopaedic units in the country.  It is possible that many of 
these orthopaedic units will be forced to consider fast-track surgery and recovery 
protocols to cope with the increased demand for primary hip arthroplasty.  These 
protocols aim to shorten postoperative LoS, reduce complications, and allow for more 
efficient financial expenditure and resource allocation per patient.  An understanding of 
which characteristics are associated with extended postoperative length of stay (EPLoS) 
in primary hip arthroplasty patients would have important implications for fast-track 
postoperative protocols being implemented in South African settings.  This was the 
impetus for the current study. 
 
This study was a retrospective chart review involving 185 South African primary hip 
arthroplasty patients.  Univariate and multivariate data analysis were performed to 
identify crude and independent associations between various characteristics and 
EPLoS.  There were three preoperative risk factors (gender, fixed flexion deformity, 
patient’s maximum walking distance) and one intraoperative risk factor (extended 
duration of surgery) which were independently associated with EPLoS following 
primary hip arthroplasty in South African patients.   
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Part 1:  Literature review     
2  
  
1.1. Orthopaedic disorders of the hip 
 
 
1.1.1. Classification 
Most orthopedic disorders comprise categories of the International Classification of 
Disease 10th (ICD-10) Revision group “Diseases of the musculoskeletal system and 
connective tissue”.1  This ICD-10 group includes: arthropathies, systemic connective 
tissue disorders, dorsopathies, soft tissue disorders, osteopathies, chondropathies, and 
other unspecified musculoskeletal/connective tissue disorders.1  In addition, there are 
various ICD-10 codes for the sequelae injury/trauma to the skeletal system, such as 
fractures.1  The most important orthopedic disorders of the hip includes: osteoarthritis 
(OA), rheumatoid arthritis (RA), avascular necrosis (AVN), fracture, malignancy, and 
joint infection.2  Hip pain and functional limitation are frequent presenting features.3   
 
 
1.1.2. Prevalence and burden of disease 
The global prevalence of hip disorders such as OA and RA have been estimated from 
data collected as part of the Global Burden of Disease Study.4-6 The age-standardized 
global prevalence of hip OA was estimated at 0.85%, with no significant change noted 
between 1990 and 2010.5  Of the 291 conditions investigated as part of the Global 
Burden of Disease Study, OA was ranked 11th most important contributor to global 
disability and the 38th most important condition related to disability-adjusted life years 
(DALYs).5  The global prevalence of RA was estimated at 0.24%, with no significant 
change in prevalence noted between 1990 and 2010.6  A systematic review of 
prevalence studies of hip arthritis in sub-Saharan African settings by Usenbo et al., 
reported the prevalence of OA in the region to be between 0.4% and 29.7% in the 
general population, and up to 87% in elderly populations.7  Hospital-based studies 
reported the prevalence of OA to be between 0.3% and 14.8%.   In the same systematic 
review, the prevalence of RA in sub-Saharan Africa was reported to be up to 5.7% in 
population-based studies and 0.7% in hospital-based studies.7  Rheumatoid arthritis-
associated DALYs increased from 3.3 million in 1990 to 4.8 million in 2010, with RA 
ranked as the 42nd most important cause of global disability.6  With regard to 
economics, arthritis (both OA and RA) accounts for considerable healthcare 
expenditure, with one American study estimating the costs associated with arthritis in 
2003 at $322 billion.8   
 
The prevalence of AVN in the general population is difficult to estimate.  There are 
thought to be 20000 to 30000 new cases of AVN in the United States each year.9  It is 
estimated that only 10% of all hip arthroplasties are performed in patients with a 
primary indication for surgery of AVN.9  More recently, the prevalence of AVN has 
been progressively increasing in populations with HIV infection.10  This has economic 
and resource implications for orthopaedic surgeons in sub-Saharan Africa, which is a 
region severely impacted by HIV infection.11   
 
Trauma/injury continues to be an important cause of morbidity worldwide.12 Hip 
fracture is a common pathology associated with trauma/injury to the hip.2,3  It is the 
primary indication for a large proportion of hip arthroplasties, with one American 
database study projecting that 23.8% of all primary hip arthroplasties in 2012 were in 
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patients with hip fractures.13  Data from a large cohort consortium of middle-aged and 
elderly Europeans and North Americans reported that 5964 DALYs (27 per 1000 
individuals) were lost due to hip fractures.14  There are also considerable economic costs 
associated with this orthopaedic disorder.15,16   
 
Malignancies affecting the hip are much rarer than OA, RA, or trauma/injury.  A recent 
audit of 117 patients with solid orthopaedic tumours from a South African setting found 
that the pelvis and proximal femur were affected in ten patients (8.5%).17  Six of the ten 
patients had osteosarcoma (60%), three had chondrosarcoma (30%) and one had 
fibrosarcoma (10%).17  In addition, a proportion of bone cancer is the result of 
metastasis.18,19  Although malignancy of the bone is not amongst the most important 
malignancies worldwide in terms of DALYs,20 it is still a considerable contributor to 
reduced quality of life.21  The estimated cost of malignancies affecting bone in the 
United States is $12.6 billion.19  Infection of prosthetic hip devices is an important 
complication of hip arthroplasty.22  An average of 1.2% of all primary hip arthroplasties 
are complicated by infection.23  In fact, up to 5.5% of revision hip arthroplasties are 
attributed to infection.24  The most common microorganism isolated from infected hips 
are Staphylococcus aureus and coagulase-negative staphylococci.23  In some settings, 
infection might increase the costs associated with arthroplasty by up to 61%.25    
 
 
1.1.3. Risk factors 
Risk factors for orthopaedic disorders of the hip include various patient, clinical, and 
procedural variables.  Risk factors for each disorder are presented in Table I.   
 
 
Table I:  Risk factors for orthopaedic disorders of the hip* 
Disorder Risk factors 
 
Osteoarthritis Obesity, physical activity, prior injury, genetics 
Rheumatoid arthritis Diet, smoking, hormones, genetics 
Osteonecrosis Femoral head fracture, hip dislocation, radiation, sickle 
cell disease, Caisson disease, myeloproliferative disorders, 
corticosteroids, alcoholism, coagulopathy, 
haemoglobinopathy, dysbaric phenomena, autoimmune 
disease, smoking, hyperlipidaemia, HIV-antiretrovirals 
Hip fracture Age, gender, race, low bone mass, low body weight, 
hormones, prior fracture, fall, disability/immobilization, 
low physical activity, psychotropic/anxiolytic/hypnotic 
drug use, corticosteroids, micronutrient deficiency, 
smoking, alcoholism, diabetes 
Malignancy Genetics/hereditary, age, gender, metastasis 
Infection (postoperative) Age, gender, race, indication for surgery, comorbidities, 
illness severity, trauma, NNIS score, income, preoperative 
length of stay, surgery duration, hospital and surgeon 
volume 
*Compiled from various published sources22,26-31 
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1.2. Hip arthroplasty 
 
 
1.2.1. Utilization 
Hip arthroplasty is one of the most common surgical procedures performed worldwide.  
Trends in hip arthroplasty utilization across the world have been summarized in a large, 
multinational database study by Pabinger and Geissler,32 and a systematic review of the 
published literature by Singh.33  In their analysis data from several countries belonging 
to the Organization for Economic Co-operation and Development (OECD), Pabinger 
and Geissler reported that the number of hip arthroplasties had increased since 2000.32  
A high level of variation in hip arthroplasty utilization between OECD countries was 
also observed, with procedure rates ranging from over 200 per 100000 population 
(United States, Germany, and Switzerland) and 8 per 100000 population (Mexico).32  
Access to care due to economic factors was correlated with hip arthroplasty 
utilization.32  The systematic review by Singh also reported an increasing trend in hip 
arthroplasty over the past three decades.33  Variation in country rates was attributed to 
differences in socioeconomic status, health care delivery systems, patient preferences, 
or the prevalence of osteoarthritis.33  Ethnic, gender, and country disparities were also 
reported in the systematic review.33  Descriptions of hip arthroplasty utilization in 
African settings are rare.  Preliminary results from a survey of South African 
orthopaedic surgeons found that 4031 hip arthroplasties are performed each year in the 
country, with fully cemented hip arthroplasty being the most popular choice (58.3% of 
procedures).34    
 
 
1.2.2. Length of stay following hip arthroplasty: Why is it important? 
Length of stay (LoS) in hospital settings refers to the duration of a single hospital 
admission, calculated as the difference in inpatient days between hospital admission and 
hospital discharge.  Postoperative LoS refers to the number of inpatient days between a 
surgical procedure and hospital discharge.  Extended postoperative LoS is an additional 
duration of inpatient days above that which would be usually expected for a specific 
population of surgical patients, and is defined as a LoS following a surgery which is 
postoperative length of stay ≥75th percentile calculated for the specific surgical 
population. In general, LoS is used as a metric for quality of care and resource 
utilization/healthcare expenditure.35,36  Specifically, increased LoS is associated with 
suboptimal quality of care and increased resource utilization/healthcare expenditure.35,36  
As such, increased LoS has important implications related to public health planning and 
the allocation of budgets and resources in hospital settings.  In response to the trend 
towards increased hip arthroplasty utilization in several countries around the world,32,33 
fast-track postoperative protocols have been proposed in some settings to ensure that 
hospital budgets and resources are more efficiently allocated per patient requiring the 
procedure.37  Fast-track protocols in surgical settings are a co-ordinated peri-operative 
approach aimed at reducing surgical stress and facilitating post-operative recovery.  
With specific reference to hip arthroplasty, dedicated surgical  units have evolved with a 
well-defined organisational set-up tailored to deliver an accelerated peri-operative 
course of fast-track surgical procedures aimed at reduction of peri-operative morbidity, 
physiologically optimised anaesthetic procedures, optimised pain management and 
aggressive mobilization.37  The postoperative LoS following standard hip arthroplasty 
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protocols is usually 7-8 days.38-40  Studies of fast-track protocols show that 
postoperative LoS can be successfully shortened to two days in hip arthroplasty 
patients.37  Therefore, aspects related to LoS following the procedure have also gained 
added importance in settings where fast-track postoperative protocols are being 
developed.   
 
 
1.2.3. Characteristics associated with length of stay following hip arthroplasty 
There are a few studies which describe LoS and associated characteristics in well-
resourced and resource-constrained settings.38-40  Older age, higher American Society of 
Anesthesiologists (ASA) Score, prolonged surgery, long surgical incisions, female 
gender, low Harris Hip Score, and not using a non-steroidal anti-inflammatory drug 
(NSAID) are amongst the common characteristics associated with increased LoS 
following hip arthroplasty (Table II).38-40  It is possible that some of the preoperative 
characteristics (ie. Age, ASA score, gender, Harris Hip Score, and NSAIDs) can be used 
to predict those patients who would benefit/not benefit from fast-track postoperative 
protocols prior to these patients actually having their procedures.  This could reduce 
postoperative complication rates in settings with fast-track protocols by ensuring only 
suitable patients are considered for fast-track postoperative protocols.        
 
Table II:  Risk factors for increased length of stay following hip arthroplasty 
Study authors (Year) Country  Identified risk factors 
 
Foote et al., (2009)38 UK Morbid obesity, older age, female, higher ASA 
score, cemented cup, longer surgical incision, 
omega surgical approach, longer operating time 
Abbas et al., (2011)39 Pakistan Older age, female, higher ASA score  
Dall et al., (2009)40 UK Older age, female, day of week when surgery 
performed, year of surgery, comorbidities, 
NSAIDs not used, aspirin used, smoking status, 
haemoglobin level, consultant level, Harris Hip 
Score  
 
 
1.3. Gap in the knowledge 
Published LoS data for primary hip arthroplasty patients is sparse, particularly from 
orthopaedic units in resource-constrained settings.  The paucity of published LoS data 
from these settings might complicate efforts to provide an efficient orthopaedic surgical 
service in these settings.  It is therefore important that the paucity in the knowledge 
regarding LoS following primary hip arthroplasty in resource-constrained settings be 
addressed.  
 
 
1.4. Problem statement 
There is a triple burden of disease in South Africa which includes communicable 
disease, non-communicable disease, and trauma/injury.41  As a consequence of this 
triple burden of disease, a proportion of the South African population will likely 
develop hip disorders.  Conservative management may not be effective in reducing pain 
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or improving functional limitation, and surgery might be the only viable option for these 
patients.33  Indeed, hip arthroplasty has become one of the most common surgical 
procedures performed in South Africa, with some orthopaedic surgeons in the country 
performing up to 43 procedures annually.34   This is compounded by the lack of 
qualified orthopaedic surgeons in neighbouring Southern African states, which has 
resulted in many non-South African patients seeking hip arthroplasty in South Africa.42   
Accelerated or fast-track postoperative care protocols are being considered as a possible 
method of coping with the increased demand for hip arthroplasty in South Africa.37,43  
These protocols aim to shorten postoperative LoS, reduce complications, and allow for 
more efficient financial expenditure and resource allocation per patient.37  Therefore, an 
understanding of which characteristics are associated with extended postoperative 
length of stay (EPLoS) in primary hip arthroplasty patients would have important 
implications for fast-track postoperative protocols being implemented in South African 
settings. 
 
 
1.5. Study aim and objectives 
The aim of this study was to investigate EPLoS in a sample of South African primary 
hip arthroplasty patients.  The objectives of this study were to: a). Determine the 
incidence of EPLoS in a sample of South African primary hip arthroplasty patients; and 
b). Determine which patient, clinical, and surgical characteristics are associated with 
EPLoS in a sample of South African primary hip arthroplasty patients. 
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ABSTRACT 
 
 
Background 
This study sought to determine the incidence of extended postoperative length of stay 
(EPLoS), and its associated risk factors in South African primary hip arthroplasty 
patients. 
 
Methods 
This was a retrospective chart review study of 185 adults who underwent primary hip 
arthroplasty at a quaternary South African hospital.  Data related to patient, clinical, and 
surgical characteristics were collected.  Postoperative length of stay was calculated as 
the time (in days) between the dates of surgery and discharge from hospital.  We 
defined EPLoS as any length of stay ≥75th percentile obtained for the entire study 
population.  Data were analysed using univariate and multivariate statistical methods. 
 
Results 
The incidence of EPLoS was 28.1% (95% Confidence interval - CI: 22.1-35.0%).    
Risk factors for EPLoS included: Female gender (Odds Ratio - OR: 4.63, 95% CI: 1.74-
12.34; p=0.002), missing Thomas Test assessment (OR: 4.80, 95% CI: 1.72-13.34; 
p=0.003), patient’s maximum walking distance <100m (OR: 3.05, 95% CI: 1.05-8.89; 
p=0.041), and extended duration of surgery (OR: 3.62, 95% CI: 1.31-10.01; p=0.013). 
 
Conclusion 
We provide a report of EPLoS and several associated risk factors in South African 
primary hip arthroplasty patients.    
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INTRODUCTION 
 
 
Increased global life expectancy has been linked to an higher burden of musculoskeletal 
conditions, including hip fracture and osteoarthritis.1  Untreated musculoskeletal 
conditions impact quality of life in afflicted patients and also have adverse 
consequences on healthcare expenditure and resource utilisation.1   These conditions 
would therefore have public health significance in resource-limited settings.  Aside from 
non-communicable aetiologies, the global HIV epidemic has also been linked to the 
growing prevalence of orthopaedic disorders.2  Conservative medical therapy might not 
be effective in a large proportion of patients afflicted with orthopaedic hip conditions.  
Surgical intervention remains the only viable management option in these patients.3 The 
effectiveness of primary hip arthroplasty in reversing pain and loss of function 
associated with orthopaedic hip conditions is well described.3,4 Utilization of primary 
hip arthroplasty as a surgical intervention for orthopaedic hip conditions has increased 
substantially over the past 2-3 decades, with this procedure now considered amongst the 
most common surgical procedures performed worldwide.4   
 
A survey of orthopaedic surgeon members belonging to the South African Orthopaedic 
Association reported that each member in the country performed up to 43 hip 
arthroplasties each year.5  In addition, a lack of surgical expertise and other essential 
resources in surrounding countries has resulted in a number of patients from these 
countries being referred to South African hospitals for the procedure.6  In response to 
the increasing demand for primary hip arthroplasty, it is possible that many South 
African orthopaedic surgery units will in future adopt accelerated postoperative care 
pathways, in which the length of inpatient stay (and subsequent expenditure and 
resource utilization for each patient) following surgery is reduced.7,8  An understanding 
of which patient, clinical, and surgical characteristics are associated with extended 
postoperative length of stay (EPLoS) in South African primary hip arthroplasty patients 
would have important future implications for the development of fast-track or 
accelerated surgical and recovery protocols implemented at orthopaedic surgery units in 
the country. 
 
Therefore, the objectives of this study were to: 
1.  Determine the incidence of EPLoS in a sample of South African primary hip 
arthroplasty patients. 
2.  Determine which patient, clinical, and surgical characteristics are associated with 
EPLoS in a sample of South African primary hip arthroplasty patients.    
    
 
MATERIALS AND METHODS 
 
 
Study design, study setting, and study population 
This was a retrospective chart review study involving consecutive adult patients who 
were admitted for primary hip arthroplasty through a dedicated arthroplasty unit at a 
quaternary level hospital in KwaZulu-Natal, South Africa between 23 September 2014 
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and 28 July 2016.  Inclusion/exclusion criteria for this study are presented in Table I.  
Potential participants were identified from theatre lists during the specified study period. 
 
Table I:  Inclusion and exclusion criteria for the proposed study 
Inclusion criteria Exclusion criteria 
 
Patients aged 18 years or older Patients younger than 18 years old 
Patients who underwent primary hip 
arthroplasty between 23 September 2014 
and 28 July 2016 
Patients who did not undergo primary hip 
arthroplasty between 23 September 2014 
and 28 July 2016 
Patient not previously included in study Patient previously included in study 
 
 
Data collection 
The medical records of all patients included in this study were reviewed and data related 
to various patient (Demographics), clinical (Comorbidities, presenting diagnosis, 
Thomas Test with fixed flexion deformity - FFD, etc.), and surgical characteristics 
(Nature of surgery, anaesthesia, surgical approach, duration of surgery, and 
perioperative blood transfusion) were collected using case report forms.  We also 
collected data related to the occurrence of serious perioperative complications, which 
we defined as a Grade III or above perioperative complication when using the Clavien-
Dindo classification (Includes: Organ failure, critical care admission, reoperation, and 
mortality).9 Postoperative length of stay was calculated as the time (Days) between the 
date of a patient’s operation and the date that the patient was discharged from hospital.  
The study outcome was EPLoS.  This was defined as a postoperative length of stay 
≥75th percentile calculated for the entire study population.  This definition of EPLoS has 
been used in similar surgical studies conducted in overseas settings.10,11 Data were 
transferred from the case report forms to a Microsoft Excel® spreadsheet in preparation 
for analysis.   
 
 
Data analysis 
The median length of stay for the study population was calculated and is presented with 
an interquartile range.  The incidence of EPLoS in this study was calculated using 
conventional epidemiological methods.12 The incidence of EPLoS in this study is 
presented as a percentage with 95% confidence intervals (95% CI).  Potential 
associations between various patient, clinical, and surgical characteristics and EPLOS 
were investigated using univariate (χ2 test, or Fishers Exact test) and multivariate 
(Binary logistic regression) statistical methods.  Results for the univariate statistical 
analysis are presented as frequencies and percentages.   
 
Characteristics with p<0.100 in the univariate analysis were selected for inclusion in the 
multivariate statistical analysis.  This purposeful selection of variables for inclusion in 
the multivariate analysis was done to obtain the most parsimonious model possible.13 
Model fit was assessed using a Hosmer-Lemeshow test.  Results for the multivariable 
statistical analysis are presented as odds ratios (OR) with 95% CI.  A p-value of <0.050 
was considered to be a statistically significant result.  All statistical analyses were 
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performed using the Statistical Package for the Social Sciences (SPSS) version 24.0 
(IBM Corp, USA).    
 
 
RESULTS 
 
 
Derivation of the study population and the incidence of EPLoS 
The derivation of the study population and the incidence of EPLoS in this study is 
shown in Figure 1.  Following the application of our study inclusion and exclusion 
criteria, our final study population consisted of 185 adult patients who underwent 
primary hip arthroplasty.  The median postoperative length of stay for the study 
population was 5.0 days (Interquartile range: 3.0-7.0 days).  The 75th percentile for the 
study population postoperative length of stay was 7.0 days.  A total of 52/185 patients 
experienced EPLoS following primary hip arthroplasty, with the calculated incidence of 
EPLoS being 28.1% (95% CI: 22.1-35.0%).     
 
Figure 1:  Study profile and incidence of EPLoS  
 
EPLoS: Extended postoperative length of stay 
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Distribution of patient, clinical, and surgical characteristics in the study population 
The distribution of patient, clinical, and surgical characteristics in the study population 
is shown in Table II.  A total of 43/185 patients were elderly (23.2%).  There was a 
higher proportion of female patients versus male patients in the study population (55.1% 
versus 44.9%, respectively).  With regard to comorbidity, 38.4% (71/185) of the study 
population were classified as having severe systemic disease (An American Society of 
Anesthesiologists score of ≥3).  The most prevalent comorbidities in the study 
population were hypertension (n/N=86/185, 46.5%), obesity (n/N=84/185, 45.4%), and 
anaemia (n/N=53/185, 28.6%).  Osteoarthritis was the most common presenting 
diagnosis (n/N=80/185, 43.2%), followed by osteonecrosis (n/N=61/185, 33.0%) and 
other miscellaneous orthopaedic diagnoses (n/N=44/185, 23.8%).  The most frequent 
miscellaneous diagnoses reported were hip dysplasia (11/44 patients 25.0%), fracture 
(9/44 patients, 20.5%), ankylosis (8/44 patients 18.2%), and rheumatoid arthritis (7/44 
patients, 15.9%).  Fixed flexion deformity (As per the Thomas Test) was established for 
138/185 patients (74.6%).  Overall, 13.5% of the study population were classified as 
having severe hip deformation (FFD >30 degrees). A total of 138/185 patients (74.6%) 
used an assistive device for mobilisation.  Pain scores (Visual Analogue Score - VAS) 
could only be established for 121/185 patients (65.4%).  A total of 99/185 patients had a 
VAS ≥7 (53.5%).  We could only establish maximum walking distance for 58.4% 
(n/N=108/185) of the study population.  A total of 52/185 patients (28.1%) could not 
walk 100m or more.  The median duration of surgery for the study population was 100.0 
minutes (Interquartile range: 75.0-125.0 minutes).  Urgent/emergent surgical procedures 
were rare in the study population (n/N=3/185, 1.6%).  Surgery was performed under 
general anaesthesia in 96/185 patients (51.9%).  The standard posterior approach was 
used in 123/185 procedures (66.5%).  Thirty-five patients (18.9%) experienced surgery 
of extended duration, which we defined as a surgery with a duration ≥75th percentile 
calculated for the entire study population.  Twenty-six patients in the study population 
required a perioperative blood transfusion (14.1%).  Serious perioperative complications 
were rare (n/N=5/185, 2.7%).       
 
 
Results of the univariate statistical analysis 
The results of the univariate statistical analysis are also shown in Table II.  The 
proportions of several characteristics were statistically similar (p≥0.050) between 
patients who experienced EPLoS and patients who did not experience EPLoS.  These 
characteristics included:  Elderly age (p=0.130), American Society of Anesthesiologists 
Score (p=0.306), current smoker (p=0.061), cardiovascular disease (p=0.999), chronic 
obstructive pulmonary disease (p=0.327), HIV (p=0.764), diabetes (p=0.999), anaemia 
(p=0.970), obesity (p=0.807), hypertension (p=0.056), mobilisation with an assistive 
device (p=0.937), VAS (p=0.774), urgent/emergent surgery (p=0.560), general 
anaesthesia (p=0.739), and posterior surgical approach to the hip (p=0.216).  The 
proportions of the remaining characteristics were statistically different (p<0.050) 
between patients who experienced EPLOS and patients who did not experience EPLoS.  
These characteristics included: Gender (p<0.001), presenting diagnosis (p=0.011), FFD 
(p<0.011), patient’s maximum walking distance (p=0.009), extended duration of 
surgery (p=0.003), perioperative blood transfusion (p<0.001), and serious perioperative 
complications (p=0.023).  We were unable to compute statistics for the characteristic 
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“renal impairment”, as we found that no patients in our study population actually had 
this characteristic. 
 
Table II:  Distribution of patient/clinical characteristics in the study population and 
results of the univariate statistical analysis* 
Clinical Characteristic All patients 
(N=185) 
No EPLoS 
(n=133) 
EPLoS 
(n=52) 
p-value 
 
 
Age >65 years old    0.130 
Yes 43 (23.2) 27 (20.3) 16 (30.8)  
No 142 (76.8) 106 (79.7) 36 (69.2)  
Gender    <0.001 
Female 102 (55.1) 60 (45.1) 42 (80.8)  
Male 83 (44.9) 73 (54.9) 10 (19.2)  
ASA score ≥3    0.306 
Yes 71 (38.4) 48 (36.1) 23 (44.2)  
No 114 (61.6) 85 (63.9) 29 (55.8)  
Current smoker    0.061 
Yes 42 (22.7) 35 (26.3) 7 (13.5)  
No 143 (77.3) 98 (73.7) 45 (86.5)  
Cardiovascular disease    0.999 
Yes 10 (5.4) 7 (5.3) 3 (5.8)  
No 175 (94.6) 126 (94.7) 49 (94.2)  
COPD    0.327 
Yes 21 (11.4) 17 (12.8) 4 (7.7)  
No 164 (88.6) 116 (87.2) 48 (92.3)  
HIV    0.764 
Yes 40 (21.6) 105 (78.9) 40 (76.9)  
No 145 (78.4) 28 (21.1) 12 (23.1)  
Diabetes     0.999 
Yes 17 (9.2) 12 (9.0) 5 (9.6)  
No 168 (90.8) 121 (91.0) 47 (90.4)  
Renal impairment    UC 
Yes 0 (0.0) 0 (0.0) 0 (0.0)  
No 185 (100.0) 133 (100.0) 52 (100.0)  
Anaemia    0.970 
Yes 53 (28.6) 38 (28.6) 15 (28.8)  
No 132 (71.4) 95 (71.4) 37 (71.2)  
Obesity    0.807 
CNBE 11 (5.9) 7 (5.3) 4 (7.7)  
Yes 84 (45.5) 61 (45.8) 23 (44.2)  
No 90 (48.6) 65 (48.9) 25 (48.1)  
Hypertension    0.056 
Yes 86 (46.5) 56 (42.1) 30 (57.7)  
No 99 (53.5) 77 (57.9) 22 (42.3)  
Presenting diagnosis    0.011 
Other 44 (23.8) 25 (18.8) 19 (36.6)  
Osteonecrosis 61 (33.0) 51 (38.3) 10 (19.2)  
Osteoarthritis 80 (43.2) 57 (42.9) 23 (44.2)  
FFD >30 degrees    0.011 
CNBE 47 (25.4) 26 (19.6) 21 (40.3)  
Yes 25 (13.5) 18 (13.5) 7 (13.5)  
No 113 (61.1) 89 (66.9) 24 (46.2)  
Mobilises with assistive device     0.937 
Yes 138 (74.6) 99 (74.4) 39 (75.0)  
No 47 (25.4) 34 (25.6) 13 (25.0)  
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VAS ≥7    0.774 
CNBE 63 (34.1) 47 (35.3) 16 (30.8)  
Yes 99 (53.5) 69 (51.9) 30 (57.7)  
No 22 (12.4) 17 (12.8) 6 (11.5)  
 
Walking distance <100m    0.009 
CNBE 77 (41.6) 59 (44.4) 18 (34.6)  
Yes 52 (28.1) 29 (21.8) 23 (44.2)  
No 56 (30.3) 45 (33.8) 11 (21.2)  
Urgent/emergent surgery    0.560 
Yes 3 (1.6) 3 (2.3) 0 (0.0)  
No 182 (98.4) 130 (97.7) 52 (100.0)  
Surgery with general anesthesia    0.739 
Yes 96 (51.9) 68 (51.1) 28 (53.8)  
No 89 (48.1) 65 (48.9) 24 (46.2)  
Posterior approach to hip    0.216 
Yes 123 (66.5) 92 (69.2) 31 (59.6)  
No 62 (33.5) 41 (30.8) 21 (40.4)  
Extended duration of surgery    0.003 
Yes 35 (18.9) 18 (13.5) 17 (32.7)  
No 150 (81.1) 115 (86.5) 35 (67.3)  
Perioperative blood transfusion    <0.001 
Yes 26 (14.1) 10 (7.5) 16 (30.8)  
No 159 (85.8) 123 (92.5) 36 (69.2)  
Perioperative complication    0.023 
Yes 5 (2.7) 1 (0.8) 4 (7.7)  
No 180 (97.3) 132 (99.2) 48 (92.3)  
*Results expressed as frequencies (%). 
p<0.050 was considered a statistically significant result 
EPLOS: Extended postoperative length of stay; ASA: American Society of Anesthesiologists; COPD: 
Chronic obstructive pulmonary disease; UC: Unable to compute; CNBE: Could not be established; FFD: 
Fixed flexion deformity; VAS: Visual analogue score. 
 
 
Results of the multivariable statistical analysis 
The results of the multivariable statistical analysis are shown in Table III.  Only nine of 
the characteristics investigated in the univariate analysis met the criteria of p<0.100 for 
inclusion in the multivariable analysis.  These characteristics were gender, being a 
current smoker, hypertension, presenting diagnosis, FFD, patient’s maximum walking 
distance, extended duration of surgery, perioperative blood transfusion, and serious 
perioperative complications.  Of these characteristics, only four were found to be 
independently associated with EPLOS.  These characteristics were female gender (when 
compared with males. OR: 4.63, 95% CI: 1.74-12.34; p=0.002), missing Thomas Test 
assessment (when compared with the reference of Thomas Test FFD ≤30 degrees. OR: 
4.80, 95% CI: 1.72-13.34; p=0.003), patient’s maximum walking distance <100m 
(when compared with the reference of walking distance ≥100m. OR: 3.05, 95% CI: 
1.05-8.89; p=0.041), and extended duration of surgery (when compared with surgery 
duration <75th percentile obtained for the entire study population. OR: 3.62, 95% CI: 
1.31-10.01; p=0.013).  The result for the Hosmer-Lemeshow test indicated adequate 
model fit (p>0.050).   
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Table III:  Results of the multivariate statistical analysis* 
Clinical Characteristic OR (95% CI) p-value 
 
Gender   
Female 4.63 (1.74-12.34) 0.002 
Male Reference - 
Current smoker   
Yes 1.15 (0.36-3.66) 0.817 
No Reference - 
Hypertension   
Yes 1.36 (0.59-3.11) 0.470 
No Reference - 
Presenting diagnosis   
Other 2.25 (0.83-6.13) 0.113 
Osteonecrosis 0.70 (0.24-2.01) 0.507 
Osteoarthritis Reference - 
FFD >30 degrees   
CNBE 4.80 (1.72-13.34) 0.003 
Yes 0.52 (0.14-1.91) 0.326 
No Reference - 
Walking distance <100m   
CNBE 0.48 (0.15-1.53) 0.214 
Yes 3.05 (1.05-8.89) 0.041 
No Reference - 
Extended duration of surgery   
Yes 3.62 (1.31-10.01) 0.013 
No Reference - 
Perioperative blood transfusion   
Yes 2.35 (0.80-6.88) 0.120 
No Reference - 
Perioperative complication   
Yes 11.77 (0.95-145.54) 0.055 
No Reference - 
*Results adjusted for confounders.  Only characteristics with p<0.100 in the univariate statistical analysis 
included in the multivariable statistical analysis. 
p<0.050 was considered a statistically significant result. 
OR: Odds ratio; CI: Confidence interval; FFD: Fixed flexion deformity; CNBE: Could not be established. 
 
 
DISCUSSION 
 
 
The median postoperative length of stay in our South African study population was 
much shorter than that reported for British, American, and Pakistani patient populations 
undergoing primary hip arthroplasty (Median of 5 days in our study population versus 
7-8 days in the other primary hip arthroplasty populations).10,14-16  South Africa is 
severely impacted by high levels of non-communicable disease,17 trauma/injury,18 and 
HIV infection,19 all of which are associated with the development of 
musculoskeletal/orthopaedic disease.20-23  This has resulted in a growing demand for hip 
arthroplasty in the country.6  However there are staffing and economic challenges in 
running orthopaedic surgical units in the public sector,24 and the availability of beds in 
these public hospitals might also be a concern.25  In order to cope with the higher 
demand for hip arthroplasty, some hospitals are beginning to implement fast-track 
protocols which are aimed at reducing postoperative length of stay while minimising the 
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rate of post-discharge complications in suitable patients who undergo the surgical 
procedure.26  This might possibly explain the difference in median postoperative length 
of stay following primary hip arthroplasty between South African and overseas 
populations.10,14-16  With regard to EPLoS following hip arthroplasty, the literature is 
scant.  However, there is one American study which reported EPLoS in this surgical 
population.10  In that study, the 75th percentile for the population postoperative length of 
stay was 14.0 days, which is twice that reported for our study.10  Furthermore, one-third 
of the American study population experienced EPLoS.10  As with our findings for 
median postoperative length of stay, the discrepancy in EPLoS between the American 
study population and our South African study population must be viewed in the context 
of a growing demand for hip arthroplasty in South Africa and the disproportionate 
availability of healthcare resources between South African and American settings.27  
 
We found statistically significant univariate associations between several characteristics 
(Including:  Gender, presenting diagnosis, FFD, patient’s maximum walking distance, 
extended duration of surgery, perioperative blood transfusion, and serious postoperative 
complications).  These findings are not unique to our study.  Other overseas studies 
have reported univariate statistical associations between these/similar characteristics and 
postoperative length of stay in hip arthroplasty patients.14,16  We found four 
characteristics to be independently associated with EPLoS (Including: Gender, FFD, 
patient’s maximum walking distance, and extended duration of surgery).  Female 
gender was found to be associated with an almost five-fold increase in the risk of 
experiencing EPLoS following primary hip arthroplasty.  Abbas et al., reported an 
almost 2-fold increase in the risk of EPLoS for women undergoing hip arthroplasty in a 
Pakistani setting.16 Dall et al., also reported a multivariate statistical association 
(without describing the magnitude of risk) between female gender and longer 
postoperative length of stay a British hip arthroplasty population.14 Therefore our 
findings for female gender appear, in general, to be in agreement with the published 
literature.  However, the difference in the magnitude of odds ratios for female gender 
obtained in our study and the study of Abbas et al.16 requires further investigation. The 
characteristics FFD and patient’s maximum walking distance have not been specifically 
investigated as potential risk factors for EPLoS following hip arthroplasty in the 
published literature.  However, these characteristics are components of the preoperative 
Harris Hip Score,28 which has been shown by Dall et al.,14 to be associated with length 
of stay following hip arthroplasty.  Specifically, these characteristics appear to be 
associated with mobility and functional status in patients with hip conditions.28 In our 
study, the reason for FFD not being established in some patients was that these patients 
had severe pain, which is also related to functional status and the ability to ambulate.  
Therefore, our findings highlight the potential importance of preoperative functional 
status and ambulation on the postoperative recovery period in South African primary 
hip arthroplasty patients.  Lastly, we found extended duration of surgery to be 
associated with an almost four-fold higher risk of experiencing EPLoS.  This is 
somewhat in agreement with the British study of Foote et al., who also report extended 
duration of surgery to be independently associated with a higher risk of EPLoS.15  
However, as with gender, there appears to be a difference in the magnitude of odds 
ratios for surgery duration between our study and the study of Foote and colleagues.15  
Attempts to should be made to reduce the duration of hip arthroplasty in our setting, 
possibly through the application of benchmarks and optimisation of surgical technique.  
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The risk factors identified in our study can be incorporated into future risk stratification 
systems for EPLoS in South African orthopaedic units.  Similar risk stratification 
systems based on identified risk factors for EPLoS following primary hip arthroplasty 
have been proposed by Abbas et al.,16 and Foote et al.15  These risk stratification 
systems are required to be developed and validated for performance in a separate 
surgical cohort.29  This step is beyond the scope of the dataset used in our study, and 
requires further research.   
 
There were several characteristics which were not found to be associated with EPLoS 
during the univariate statistical analysis, or following inclusion in the multivariable 
statistical analysis.  There are two explanations for the lack of statistical association 
between these characteristics and EPLoS in our study.  Firstly, it might be possible that 
these characteristics, while identified as risk factors in overseas settings, are genuinely 
not associated with EPLoS in South African hip arthroplasty patients.  Discordance in 
clinical risk factors between overseas/South African surgical populations and other 
postoperative outcomes has been described elsewhere.30  It might be worthwhile to 
involve overseas collaborators with access to overseas patient data in future research 
such that valid comparisons of risk factors between our settings can be made.   
Secondly, it is possible that a larger sample size than 185 patients would be required to 
investigate the impact of these characteristics on EPLoS.  A potential solution to this 
would be a collaborative study involving as many hospitals which offer orthopaedic 
surgical services as possible. 
 
Our study had several strengths.  Our study is, to the best of our knowledge, the only 
South African study which specifically investigates EPLoS following primary hip 
arthroplasty.  Another strength of our study is that we included data on HIV infection in 
our statistical analyses.  This is important as the prevalence of HIV is usually much 
lower in American and British populations,19 and so our study provides important 
information on the impact of this characteristic in settings with a high burden of HIV 
infection.  The final strength of our study is that while our sample size appeared modest, 
it still allowed for us to perform a multivariable statistical analysis to determine 
independent risk factors for EPLoS without any serious violation of statistical rules of 
thumb.31 Our study also had several limitations.  Firstly, as this study was conducted at 
a single, dedicated arthroplasty unit in a quaternary level hospital with standardized pre 
and postoperative protocols in place, it might be argued that our study findings lack 
generalisability.  As for our solution for the challenge related to the lack of statistical 
association between several characteristics and EPLoS, we recommend that 
collaborative studies involving hospitals at various levels of service delivery are 
conducted to determine the generalisability of our study findings.  In addition, we were 
unable to investigate the impact of Harris Hip Score in our study due to poor 
documentation of this characteristic in the patient medical records.  We did however 
find that components of the Harris Hip Score were statistically associated with EPLoS, 
and it is therefore possible that the composite Harris Hip Score might also be associated 
with EPLoS.  Prospective research wherein data collection for the Harris Hip Score is 
standardised is required.  Finally, we did not report the impact of EPLoS on healthcare 
expenditure or post-discharge complications.  These outcomes can only be appropriately 
investigated through the conduct of prospective research studies.   
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In conclusion, we found several risk factors for EPLoS following primary hip 
arthroplasty in South African patients.  These risk factors included gender, FFD, 
patient’s maximum walking distance, and extended duration of surgery.  Further 
research is required to confirm our study findings, as well as address the limitations 
identified in our study.  
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BACKGROUND: 
Increased global life expectancy has been linked to an higher burden of musculoskeletal 
conditions, including hip fracture and osteoarthritis.1  Untreated musculoskeletal 
conditions impact quality of life in afflicted patients and also have adverse 
consequences on healthcare expenditure and resource utilization.1   These conditions 
would therefore have public health significance in resource-limited settings.  Aside from 
noncommunicable aetiologies, the global HIV epidemic has also been linked to the 
growing prevalence of orthopaedic disorders.2  Conservative medical therapy might not 
be effective in a large proportion of patients afflicted with orthopaedic hip conditions.  
Surgical intervention remains the only viable management option in these patients.3  
The effectiveness of primary hip arthroplasty in reversing pain and loss of function 
associated with orthopaedic hip conditions is well described.3,4  Utilization of primary 
hip arthroplasty as a surgical intervention for orthopaedic hip conditions has increased 
substantially over the past 2-3 decades, with this procedure now considered amongst the 
most common surgical procedures performed worldwide.4   
 
A survey of orthopaedic surgeon members belonging to the South African Orthopaedic 
Association reported that each member in the country performed up to 43 hip 
arthroplasty procedures a year.5  In addition, a lack of surgical expertise and other 
essential resources in surrounding countries has resulted in a number of patients from 
these countries to be referred to South African hospitals for the procedure.6  In response 
to the increasing demand for primary hip arthroplasty, it is possible that many South 
African orthopaedic surgery units will in future adopt accelerated postsurgical care 
pathways, in which the length of inpatient stay (and subsequent expenditure and 
resource utilization for each patient) following surgery is reduced.7,8   
 
An understanding of which preoperative patient/clinical characteristics are associated 
with extended postoperative length of stay (EPLOS) in a South African setting would 
contribute toward assisting public health specialists and orthopaedic surgeons deciding 
on which patients are likely to benefit or not benefit from accelerated postsurgical care 
pathways, thereby facilitating improved patient management and allocation of resources 
in these settings.  
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AIM: 
The aim of this study will be to determine which preoperative patient/clinical 
characteristics are associated with EPLOS in a sample of South African primary hip 
arthroplasty patients.    
 
 
METHODS: 
Study design, study setting, and study population: 
This will be a retrospective chart review study of adult (≥18 years old) patients who 
were admitted for primary hip arthroplasty at the Inkosi Albert Luthuli Central Hospital 
(IALCH) in Durban, South Africa between 01 January 2014 and 01 August 2016.  .  
The 846-bed hospital provides healthcare services, including surgical services, at a 
tertiary level to residents of KwaZulu-Natal Province, South Africa.  
Inclusion/exclusion criteria for the study are presented in Table 1.  Potential participants 
will be identified from the theatre lists during the specified study period. 
 
Table 1.  Inclusion and exclusion criteria for the proposed study 
Criteria 
Number 
Inclusion Criteria Exclusion Criteria 
1 Patients aged 18 years or older Patients younger than 18 years old 
2 Patients who underwent primary 
hip arthroplasty at IALCH 
between 01 January 2014 and 01 
August 2016 
Patients who did not undergo 
primary hip arthroplasty at IALCH 
between 01 January 2014 and 01 
August 2016 
3 Patient not previously included in 
study 
Patient previously included in 
study 
 
Sample size and sampling strategy: 
A brief review of operating room schedules shows that there were 216 consecutive 
eligible patients during the study period.  All 216 patients will be included in the final 
analysis of this study.  This sample size is adequate for conducting the planned 
statistical analysis if sample size rules of thumb are observed.9 
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Data source and data management: 
The electronic medical records of these 216 patients will be reviewed and data related to 
various preoperative patient and clinical characteristics will be collected and entered 
onto a de-identified, password protected database in preparation for statistical analysis.  
The specific variables to be collected are provided in a data collection form in Appendix 
1.  We will define the preoperative period as the time between hospital admission and 
surgical incision.  These preoperative patient and clinical characteristics were selected 
as they were collected as variables in similar research studies from elsewhere in the 
world.  All variables listed in Appendix 1 are routinely recorded in the clerking/doctors 
progress notes for each patient.  Preoperative comorbidity will be considered present if 
it was diagnosed by a physician prior to surgery.   Whether the procedure was elective 
or not, and the type of anaesthesia used prior to surgical incision is routinely reported in 
the doctors operative note.  Postoperative length of stay will be calculated as the time 
(in days) between the date of the operation and the date of hospital discharge.  The 
study outcome will be EPLOS, which will be defined as a postoperative length of stay 
which is longer than 75th percentile for the study population.  This outcome has been 
used in other studies of investigating EPLOS.10,11 
 
Statistical analysis: 
The incidence of EPLOS will be calculated using conventional epidemiological 
methods.  Potential statistical associations between various preoperative patient, clinical 
characteristics will be determined through univariate (Mann-Whitney test, chi-squared 
test, or Fishers exact test) and multivariable (Regression analysis) statistical methods.  
Results for the univariate analysis will be presented as medians with interquartile ranges 
or frequencies and percentages, where appropriate.  Results for the multivariable 
analysis will be presented as beta-coefficients with 95% confidence intervals.  A p-
value <0.05 will be considered statistically significant.  All statistical analyses will be 
performed using the Statistical Package for the Social Sciences version 24.0 (IBM Corp, 
USA).    
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Study approval: 
This is a sub-analysis of data being collected as part of a larger surgical quality 
improvement research initiative, which has already received approval from the 
University of KwaZulu-Natal Biomedical Research Ethics Committee (BE595/16). 
Approval/a waiver from the University of KwaZulu-Natal Biomedical Research Ethics 
Committee will still be sought prior to commencing this specific sub-analysis. 
 
POTENTIAL IMPACT OF RESEARCH: 
This study will provide important information to public health specialists and 
orthopaedic surgeons which will allow for improved patient management, and 
allocation of healthcare expenditure and healthcare resources for South African primary 
hip arthroplasty patients.   
 
 
DISSEMINATION OF STUDY RESULTS: 
The results of this research will be made available to the scientific community through 
publication in an accredited, peer-reviewed medical journal. The results of the research 
will also be reported to the KwaZulu-Natal Department of Health. A lay summary of the 
results will also be made available on selected print and electronic media, where 
possible. 
 
PROPOSED WORK PLAN (WITH REFERENCE MAY 2017- MAY 2018): 
Complete draft protocol          
Submit proposal to ethics 
and postgraduate 
committee 
         
Ethics & postgraduate 
committee approval 
         
Commence data collection       
Commence data analysis 
and prepare thesis 
         
Submit thesis for 
examination  
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Variables to be collected from patient electronic medical records 
Participant Number (For office use only): ________________________ 
 
1.  Age at hospital admission (In years):  ______________ 
2.  Gender (Male or female): __________________ 
3.  Indication for surgery (Specify): _________________________________________ 
4.  Body mass index (in kg/m2): __________________________ 
5.  American Society of Anesthesiologists Score:  _____________  
6.  Harris Hip Score: __________________ 
7.  Visual analogue score: ____________________ 
8.  Time between initial orthopaedic clinic visit and operation date (in days): _____________ 
9.  Number of crutches/assistive device used to mobilize: ________________ 
10.  Maximum distance patient can walk (in metres): _______________ 
11.  Fixed flexion deformity (degrees): _________________ 
12.  Physician-diagnosed medical comorbidities (Yes/No) 
Diabetes: ___________  
Hypertension: ______________  
Cardiovascular disease: _______________  
Asthma/obstructive pulmonary disease: __________________  
HIV: _______________ 
Tobacco use: __________________  
Anaemia:  _______________  
Renal disease: ____________________ 
13.  Preoperative chronic medications (Yes/No)  
Aspirin: __________________  
Statin: _________________  
Nonsteroidal anti-inflammatory drugs: _________________ 
Other (specify): ____________________________________ 
14.  Elective surgery (Yes/No): _____________________ 
15.  Anaesthetic induction using general anaesthesia (Yes/No): ______________ 
16.  Date of operation (DD/MM/YYYY): ________________________ 
17.  Date of hospital discharge (DD/MM/YYYY): ___________________ 
18.  Postoperative length of stay (days): _____________________  
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Appendix 2:  Journal guidelines  
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